Mondelēz International has unveiled a new range of lower calories nougat bars coated in Cadbury chocolate, containing only 91 calories, dubbed Cadbury Delights.
The range of nougat bars, which features a soft nougat filling and caramel layer inside, comprises salted caramel, orange and caramel, and hazelnut and caramel flavors.
According to Abi Eayrs, brand manager for Cadbury Delights at Mondelēz International, consumers are increasingly looking for lower-calorie snacks where they don’t have to compromise on taste or satisfaction.
Eayrs added that the lower-calorie chocolate category is growing by over 21 percent annually and their new range of Cadbury Delights presents a huge opportunity for retailers and wholesalers to drive incremental sales.
Cadbury Delights will be sold by next month for an RRP of £1.99.


Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields
Why have so few atrocities ever been recognised as genocide?
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy
Yes, government influences wages – but not just in the way you might think
Singapore GDP Grows 5.7% in Q2 2026 as AI-Driven Manufacturing Boosts Economy
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts
Oil Prices Surge as U.S.-Iran Conflict Escalates and Strait of Hormuz Risks Grow
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Disaster or digital spectacle? The dangers of using floods to create social media content
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 



